EA004647B1 - Способы потенциации внутривенного эстрамустинфосфата - Google Patents

Способы потенциации внутривенного эстрамустинфосфата Download PDF

Info

Publication number
EA004647B1
EA004647B1 EA199901081A EA199901081A EA004647B1 EA 004647 B1 EA004647 B1 EA 004647B1 EA 199901081 A EA199901081 A EA 199901081A EA 199901081 A EA199901081 A EA 199901081A EA 004647 B1 EA004647 B1 EA 004647B1
Authority
EA
Eurasian Patent Office
Prior art keywords
estramustine
estramustine phosphate
administered
phosphate
intravenous
Prior art date
Application number
EA199901081A
Other languages
English (en)
Russian (ru)
Other versions
EA199901081A1 (ru
Inventor
Майкл С. Копрески
Берил Асп
Бо Фредхольм
Пер-Олв Гуннарссон
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of EA199901081A1 publication Critical patent/EA199901081A1/ru
Publication of EA004647B1 publication Critical patent/EA004647B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EA199901081A 1998-03-27 1999-03-26 Способы потенциации внутривенного эстрамустинфосфата EA004647B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7954298P 1998-03-27 1998-03-27
PCT/US1999/004275 WO1999049869A1 (en) 1998-03-27 1999-03-26 Methods to potentiate intravenous estramustine phosphate

Publications (2)

Publication Number Publication Date
EA199901081A1 EA199901081A1 (ru) 2000-12-25
EA004647B1 true EA004647B1 (ru) 2004-06-24

Family

ID=22151209

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199901081A EA004647B1 (ru) 1998-03-27 1999-03-26 Способы потенциации внутривенного эстрамустинфосфата

Country Status (16)

Country Link
EP (1) EP1003521A4 (hu)
JP (1) JP2001508810A (hu)
KR (1) KR20010021656A (hu)
CN (2) CN1636598A (hu)
AU (1) AU750010B2 (hu)
BR (1) BR9906425A (hu)
CA (1) CA2295049A1 (hu)
EA (1) EA004647B1 (hu)
HU (1) HUP0200547A3 (hu)
ID (1) ID24504A (hu)
IL (1) IL133612A0 (hu)
NO (1) NO20002343D0 (hu)
NZ (1) NZ501987A (hu)
PL (1) PL342969A1 (hu)
WO (1) WO1999049869A1 (hu)
ZA (1) ZA997821B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
US6436913B1 (en) * 2000-07-25 2002-08-20 Pharmacia & Upjohn Company Use of estramustine phosphate in the treatment of bone metastasis
RU2471511C1 (ru) * 2011-05-04 2013-01-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "РНИОИ" Минздравсоцразвития России) Способ лечения метастазов в печень рака толстой кишки

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617292A (ja) * 1984-06-20 1986-01-13 Japan Atom Energy Res Inst 制癌剤を結合させたエストラサイト系化合物を製造する方法
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
WO1993018751A1 (en) * 1992-03-23 1993-09-30 Georgetown University Liposome encapsulated taxol and a method of using the same
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.

Also Published As

Publication number Publication date
NO20002343L (no) 2000-05-04
CA2295049A1 (en) 1999-10-07
EA199901081A1 (ru) 2000-12-25
HUP0200547A3 (en) 2003-07-28
AU3353399A (en) 1999-10-18
NZ501987A (en) 2002-10-25
CN1273530A (zh) 2000-11-15
PL342969A1 (en) 2001-07-16
ZA997821B (en) 2000-08-01
AU750010B2 (en) 2002-07-11
BR9906425A (pt) 2000-07-11
NO20002343D0 (no) 2000-05-04
EP1003521A4 (en) 2003-07-23
JP2001508810A (ja) 2001-07-03
IL133612A0 (en) 2001-04-30
ID24504A (id) 2000-07-20
CN1636598A (zh) 2005-07-13
EP1003521A1 (en) 2000-05-31
WO1999049869A1 (en) 1999-10-07
HUP0200547A2 (hu) 2002-07-29
KR20010021656A (ko) 2001-03-15

Similar Documents

Publication Publication Date Title
US6461637B1 (en) Method of administering liposomal encapsulated taxane
US6146659A (en) Method of administering liposomal encapsulated taxane
Cabanes et al. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel.
JP2009292850A (ja) 抗癌治療
Galano et al. Efficacy and tolerability of vinorelbine in the cancer therapy
van Hoogevest et al. The use of phospholipids to make pharmaceutical form line extensions
US6495585B2 (en) Method for treating hyperproliferative tissue in a mammal
EA004647B1 (ru) Способы потенциации внутривенного эстрамустинфосфата
CA2831848C (en) Combination comprising (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide and a taxane
Calderoni et al. Taxanes in lung cancer: a review with focus on the European experience
US6849616B1 (en) Methods to potentiate intravenous estramustine phosphate
AUen Stealth® Liposomes as a Drug Sustained Release System for 1-PD-Arabinosy lfuranosy lcytosine (Cytosine Arabinoside)
Franchin et al. Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers. A single‐institution study
US7314637B1 (en) Method of administering liposomal encapsulated taxane
Tsavaris et al. A simplified premedication schedule for 1-hour paclitaxel administration
Milano et al. Recent patents on the efficacy and tolerability of vinorelbine in the cancer therapy
CZ465599A3 (cs) Způsoby potenciace intravenosního estramustinfosfátu
MXPA00000198A (en) Methods to potentiate intravenous estramustine phosphate
ES2315429T3 (es) Procedimiento para afectar la progresion neurologica.
Higgins Trials begin for unique immunomodulatory anticancer agent
Nabholtz Share this story: RELATED ARTICLES
Nitschea et al. Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-α in pancreatic and periampullary cancer: Results of a feasibility study Chimioradiothérapie et immunothérapie avec 5-fluoro-uracile, cisplatine et interféron-α dans les cancers du pancréas et périampullaires: résultats d’une étude de faisabilité
AU2009326220A1 (en) Antitumor combination combining AVE8062 and docetaxel
NZ616410B2 (en) Combination treatment of cancer
MXPA00002170A (en) A method of administering liposomal encapsulated taxane

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU